Independent clinical trials examining the complete myGLP system do not exist yet
Important limitations of the COBRRA trial were that it was open-label, followed-up patients for only three months, and excluded some important groups, including patients with active cancer and those weighing more than about 265 pounds
What we do have is a narrow slice of human data from one proof-of-concept clinical trial [3] , early-phase pharmacokinetic work in healthy volunteers [2] , and a set of theoretical concerns from ipamorelin's mechanism that have not been observed in humans but follow logically from what the compound does
This makes it an ideal route for peptide delivery
We review your symptoms, past injuries, imaging, medical history, and current medications, then discuss your goalswhether thats returning to a specific sport, speeding recovery after surgery, or simply walking and exercising comfortably again